Synairgen Share Discussion Threads

[wetdream] 03/4/2020 10:12

This is a news-driven share.
Friday’s usually a ‘down’ day, just in case sh!t happens.
SP will probably drift around 50p, imho.

[talk2dubya] 03/4/2020 09:24

It’s sad to see the lengths some will go to , it is counter productive if you are an investor

[jev1] 03/4/2020 09:22

Talk2

Would be great if it was !

[nobbygnome] 03/4/2020 09:16

Careful PI you are now on a yellow card.

Why so rude...

[the patient investor] 03/4/2020 09:13

more stuff from Lykya, the ONLY WELL INFORMED person worth listening to, ALL the other ones are just egotistical improvised experts with ABSOLUTELY no clue

[talk2dubya] 03/4/2020 09:12

Not sure if this is genuine:

[cambourne] 03/4/2020 09:09

Seeking Alpha have done an article. Should get some $$$$ invested on a few American punts. The trials are underway, lots of patients, money ready for manufacture upscaling.

[hazl] 03/4/2020 09:09

Ah makendon.
I see .
In fairness,you're right to be cautious.
I had to 'unfollow' somebody last week because they showed too much grim reality of the sometimes, ugly world we live in.
Of course it represents each part of human nature....the good bad and the ugly.
It's about being selective as ever.
I enjoyed the vimeo thanks.

[jev1] 03/4/2020 09:08

Your nose is getting longer with each post, Duxy.

[the patient investor] 03/4/2020 09:08

"The hope is that the drug could be made SWIFTLY AVAILABLE, for example under emergency use measures, if SNG001 proves to be effective."


Synairgen doses first patients with COVID-19 drugPhil TaylorPhil TaylorMarch 31, 2020

UK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of interferon beta-1a that aims to treat coronavirus infections.

The drug is already widely used in an injectable form for multiple sclerosis, and Synairgen has already tested its inhaled version in clinical trials involving more than 200 asthma patients with a cold or flu infection, showing improvements in lung function.

The Southampton-based company says the first patient with COVID-19 has now been given SNG001 at the University Hospital Southampton NHS Foundation Trust, with another six trial sites due to start dosing additional subjects in the next few days.

Last week, Synairgen raised £14 million (around $17 million) in an oversubscribed funding round to pay for the SNG001 trial, shortly after getting a green light for the study from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA).

Interferon beta orchestrates the body’s response to a viral infection, and there is some evidence to suggest that people who get dangerously sick after being infected with SARS-CoV-2 – the virus that causes COVID-19 – have lower than usual levels of interferon beta in the lungs.

Synairgen also says viruses – including coronaviruses such as SARS-CoV-2 and MERS-CoV – have evolved mechanisms which suppress the production of interferon beta in the body, helping them evade the immune system.

If its hypothesis is correct, giving SNG001 via a nebuliser into the lungs could reduce viral replication and cell damage, hastening patients’ recovery from the infection. That’s backed up by animal data showing reduced lung viral load and lung pathology in a swine flu model of viral pneumonia.

The trial is being led by Professor Tom Wilkinson, a consultant in respiratory medicine at University Hospital Southampton and professor of respiratory medicine at the University of Southampton.

Investigators aim to enroll 100 patients in the pilot phase, expected to last about two months, and expand the study population if initial results are encouraging. The hope is that the drug could be made swiftly available, for example under emergency use measures, if SNG001 proves to be effective.

There is of course still a long way to go before that point however, and questions remain about how quickly production could be scaled up to meet demand as confirmed cases of COVID-19 hit almost 800,000 worldwide, including more than 22,100 in the UK.

“A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic,” said Richard Marsden, Synairgen’s chief executive.

The company is also close to completing a 120-patient phase 2 trial of SNG001 in chronic obstructive pulmonary disease (COPD) patients with viral infections, with 109 patients enrolled, but further recruitment has been put on hold during the pandemic to minimise the chance of vulnerable patients being exposed to COVID-19.

The start of the trial was welcomed by BioIndustry Association CEO Steve Bates, who said: “The UK life science ecosystem is stepping up across the piece on coronavirus.”

He went on: “This shows the speed at which our ecosystem can move; linking SMEs, the established UK clinical trials infrastructure of the NHS and an enabling regulator in the UK’s MHRA.”

“The sector is also working flat out on innovative emergent ventilator capacity, novel vaccine scale-up capacity, new ways to support NHS patients at home with digital products and investigating antibody technology for therapeutic use.”

[duxy786] 03/4/2020 09:06

Jev1, if it materialise in to actual news, you'll be the first in on the 'secret'.You and this board yeah?

[jev1] 03/4/2020 09:03

Funny that Duxy.

Nobody else has 'heard of it'.

Clearly it's a secret cure that only you're aware of.

Wouldn't be social distancing by any chance ?

;o)

[makendon] 03/4/2020 09:02

Re: stop loss.

Classic tree shake this morning, anyone who’d set a stop loss at 5% (naked traders get out number) of last nights close will be licking their wounds right now.

Hazl, am now a cautious user of twitter :)

[duxy786] 03/4/2020 08:57

Royal....wrong use of the word. If it makes it clear....I've just heard it's a treatment that seems to be working and may possible be fast tracked for use. Doesn't mean it can't still fail and that goes for any of the trails taking place. Nothing against SNG, am sure their trails are going just as well. It seems some companies have kept very quiet about their trials....and one such, has just popped its head up.

[bmnsa] 03/4/2020 08:55

Duxy is a proven idiot on the many threads he posts on.

[nobbygnome] 03/4/2020 08:54

51-53 during the auction

[royalalbert] 03/4/2020 08:53

Duxy how is this possible

"Some with already in trials with possible vaccines which show marked results on Covid-19 cases."

Nice to know you don't know the difference between a vaccine and a treatment.

Always a shorter are you not?

[the patient investor] 03/4/2020 08:53

A reminder of who we are.

SNG scientist detailed interview on BBC Business Daily from 12:10 two days ago

[tialouise] 03/4/2020 08:50

Your a trader , sold out now want it as low as possible . Worst piece of de- ramping

[nobbygnome] 03/4/2020 08:50

A vaccine is not relevant for us here. The earliest a vaccine is going to be available is around the end of the year. Treatment of dying patients in the next 3 or 4 months is the important, grim, relevant fact here.

[talk2dubya] 03/4/2020 08:49

Tizzylouise who are you speaking t?

[tialouise] 03/4/2020 08:48

Proof ???????